USA Roadmir, a wholly-owned subsidiary of a Korean publicly listed group, is an international R&D and manufacturing enterprise powered by biotechnology and driven by AI-enabled global cross-border technology. Focusing on black-tech BIO longevity solutions, high-end anti-aging cosmetics, and essential health supplements, the company possesses its own proprietary ingredient library and formulation system. Leveraging our parent company's global resources, we have established dual R&D centers in the United States and South Korea. Concurrently, we have built a smart tech architecture tailored for global markets—encompassing automated international compliance, intelligent supply chain management, cross-cultural customer interaction, and real-time market dynamics analytics—ensuring every product efficiently and precisely meets localized user demands worldwide. We adhere to a fully autonomous, closed-loop process from molecular design to finished product output. By empowering global business expansion through cross-border AI technology, we continuously deliver cutting-edge products and services that combine deep technological expertise with seamless market adaptability to our international partners.

Guided by scientific rigor and a global mindset, ROADMIR BIO pursues excellence across three pillars of corporate mission and industry leadership.

Explore our flagship product lines — click any product to open its full product page.

Parent Company Profile: NEXTEYE (South Korea) · Stock Code 137940.KQ

Founded on September 29, 1998, NEXTEYE initially focused on the R&D and manufacturing of industrial automation inspection equipment, providing technical support to companies such as Samsung, LG, and Hyundai Motor. It was listed on the KOSDAQ (Korea's tech-heavy board) and has grown into a major player in its field.

After receiving strategic investments from renowned Korean investment institutions including AJUIB and Aesthetic International, the company expanded into the biotechnology and beauty industries in 2010. The company completed a series of strategic moves: investing in and acquiring beauty manufacturers NEW & NEW and INS KOREA (a well-known Korean nail polish producer) as well as the plastic surgery hospital GLOWPORT; establishing the subsidiary JDML Cosmetic, which launched several market-attractive products (such as VN Sunscreen and FHD Blood Orange Mask); setting up a biology laboratory in the United States through its subsidiary Roadmir; and investing in PRP SCIENCES, which holds the exclusive license for subcutaneous injectable hyaluronic acid in Asia. Subsequently, its subsidiary INNOMETRY was successfully listed.

Over two decades of industrial accumulation and Korean listing experience have laid a solid foundation for NEXTEYE. The company will continue to focus on the frontiers of Korea–US technology, deepen R&D innovation in wellness products and bio-beauty, and leverage global resources and full-industry-chain integration to drive the continuous evolution of its brand portfolio, opening a new chapter in the beauty and health industry.

Click any base to view its full profile.

NEW&NEW is a world-class cosmetics company with a research institute spanning over 1,000 pyeong and an international cross-border cosmetics factory of over 10,000 pyeong. As the inventor of the BB cream that has led the global K-Beauty trend (every BB cream sold worldwide pays NEW&NEW a patent royalty), it is known as the "birthplace of beauty blockbusters" and the "pioneer of cosmetics innovation".

NEW&NEW also has an expert R&D team from LG Sulwhasoo in Korea and has obtained dozens of industry-leading exclusive invention patents on cosmetic ingredients and functions. Its latest microcurrent skincare technology has been fully applied across the well-known Hui Ti (HYTI) series, once again rewriting the shortest path and ultimate results of skin renewal and anti-aging, bringing new beauty opportunities to more people as technology advances with globalization!

Challenging new frontiers and creating value for health and beauty, NEW&NEW looks forward to revealing more beauty trends to you and creating a brilliant future together!

The GENE AKG Anti-Aging Research Center is the Group-invested Korean production base of GENE AKG, a world-first milestone in anti-aging.

The latest-generation anti-aging product GENE AKG was developed by a team of scientists led by Harvard medical doctors together with renowned Korean and American biomedical experts. Clinically verified by medical centers to deliver significant anti-aging benefits, it also provides excellent support for chronic conditions and brings broader, breakthrough outcomes to humanity.

GENE AKG, a world-class patented anti-aging product, sold over one million bottles within just over a month of its launch. With rapidly growing sales, it has become a global sensation and the top choice for premium anti-aging consumers. The GENE AKG Korean production base features Class 100,000 purification workshops and modern production lines with a daily output of over 50,000 units, fully meeting the needs of GENE AKG's global sales.

A new trend for health, safeguarding life. The GENE AKG Korean production base looks forward to joining you in riding a new wave of anti-aging!

The BT Longevity & Health Research Center is a high-tech biotech enterprise invested by the Group. It holds the world's largest collection of "ginsenoside" reference standards and proprietary patented technologies, focusing on deep R&D and industrialization of 150-year-old ginseng cultured root cell technology.

Groundbreaking work begins with 150-year-old natural wild ginseng root tissue, establishing a specialized culture system through precise isolation, callus induction, and cell line screening. Its proprietary patented enzyme conversion technology (ECS) precisely converts more than 20 nearly non-absorbable ginsenosides (such as Rg1 and Rb1) into easily absorbable rare ginsenosides (such as Compound-K and Rg3), boosting the average human absorption rate from 50% to over 95%. This enables 150-year-old ginseng cultured root cells to successfully cross the technical barrier from laboratory gram-scale production to industrial ton-scale manufacturing.

Looking ahead, BT will continue to advance its scientific, premium, and global strategies, leading end-to-end innovation from source cell culture to end-product application, and contributing to a healthier future with cutting-edge biotechnology.

The IZI Stem Cell Research Center, invested by the Group, houses one of the world's first and Korea's first teams to receive approval from the Ministry of Food and Drug Safety for anti-cancer cell therapy biopharmaceuticals. As a biotech enterprise leading the cell therapy revolution, it is rewriting treatment paradigms with disruptive technology at the frontiers of cancer treatment and regenerative medicine. With cutting-edge natural killer (NK) immune cell therapy and innovative umbilical cord gel stem cell technology as its twin pillars, it opens up entirely new possibilities for human health.

The NK cell therapy of the IZI Stem Cell Research Center has demonstrated industry-leading efficacy data in clinical trials for liver cancer and gastric cancer, while building complete regenerative medicine and premium medical aesthetics solutions. Backed by an international-standard GMP production system, it is accelerating its global market expansion so that innovative therapies can benefit a wider population.

Aiming for "No. 1 in Korea, world-class excellence", the IZI Stem Cell Research Center continues to drive innovation in cell therapy. It believes that precisely targeted NK cell therapy will ultimately rewrite the history of humanity's fight against cancer, redefine the boundaries of life, and define the future of cells. We look forward to joining hands with elite partners worldwide to usher in a new era of cell therapy!

• An international R&D and manufacturing enterprise powered by biotechnology at its core and an AI-driven global cross-border technology engine. The company is a US federally registered corporation invested in by Nexteye, a publicly listed Korean company.
• Dedicated to the independent R&D of cutting-edge biotechnology products and breakthrough innovation in highly active biological raw materials, it holds multiple core processes and patented formulas, building a full-chain technological barrier from raw material development to finished product output. The IEONA series life technology BIO product line has been successfully developed, featuring three core products: GeneAKG, Myo-Inositol, and 150-year-old Mountain Ginseng Cultured Root Cell Drinks - alongside the Pulsed Current GeneAKG Anti-Aging Skincare Series.
• The group boasts three laboratories operated under a US-South Korea scientist R&D alliance, along with its own GMP-compliant manufacturing facilities: a cosmetics factory, a South Korean nail product GMP factory, and a medical injection and hyaluronic acid GMP factory.
• The Group's venture capital division covers semiconductor inspection, medical aesthetics, biotechnology, cosmeceuticals, and daily chemicals. With over USD 1 billion in managed funds and peak daily stock trading volume of USD 250 million, its financial position remains solid.
• The Group currently holds controlling stakes in 7 internationally listed companies and investments in 54 companies, with a service network covering 40,000 retail outlets worldwide. Its partners include Samsung, LG, SK, Hyundai, BYD, and other renowned enterprises, earning it a strong market reputation.

• The Group is at the industry's advanced level in biomedical technology: it has obtained 141 technology patents and achieved multiple significant milestones, including the industry-leading Phase III clinical approval for human medical injectable hyaluronic acid granted by the Korean government, the 2022 launch of the genetic ingredient Gene-AKG, the 2024 release of skincare products featuring microcurrent pulse patent technology, and an ongoing liver cancer targeted regulation program.
• Committed to providing global consumers and partners with scientifically grounded, quality-controlled health products as well as efficient, cost-effective AI cross-border technical services.
• In global markets, the company strictly complies with relevant regulations, focusing on the import and sales of cross-border goods (manufactured in South Korea and the US, dispatched from bonded warehouses). Adopting the standard cross-border personal-use model, products are shipped globally from South Korea via fully compliant bonded warehouses, backed by a hassle-free 7-day return policy to effectively safeguard consumer rights.

Important Notice: In the Chinese market, if you encounter unverified rumors concerning the company involving multi-level team compensation or bonus distribution, please do not believe them, to avoid damage to your personal rights and interests.

Dedicated to first-in-class innovations and advanced formula R&D in biomanufacturing, we leverage 20 years of accumulated group-wide strength in biological and medical science R&D, integrating nearly 141 patented technologies. Through clinical trials evaluating product efficacy, we strive to make impactful contributions across life science sectors—including cosmeceuticals, medical aesthetics, age-defying solutions, anti-aging, and healthspan management—to elevate human quality of life. Currently, we have established strategic partnerships with numerous research institutions at home and abroad. Holding over 50 global patented technologies, the company enjoys a stellar reputation in South Korea, ranking among the top three in the industry.

The patent certificate wall of Korea's NEXTEYE company showcases over 50 global patented technologies; the company enjoys a prestigious reputation in the Korean industry, ranking among the top three.

On June 30, 2022, NEW&NEW, a Korean company controlled by NEXTEYE, obtained the patent certificate for "Technology for Applying Proprietary Yeast Strains to Cosmetics". This technology is currently applied by only a few cosmetics R&D companies worldwide, such as Christian Dior of France and P&G of the US. On July 19, 2023, the company received another patent certification for "Technology for Applying Microcurrent Pulses to Cosmetics", issued by the Korean Intellectual Property Office.

As a sister company in Korea, NEW&NEW will fully support Roadmir's year-round cosmetics R&D and handle global market production and supply, including the world-leading microcurrent GeneAKG Aurora anti-aging series.